ELOXX PHARMACEUTICALS, INC. ELOX Cash Flow

Eloxx pharmaceuticals, inc. (ELOX)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12
Cash flows from operating activities:
Net loss
-52,903	-50,874	-53,268	-51,554	-50,511	-47,185	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-8,612	-8,279	-5,554	-5,955	-9,020	-8,267	-8,022	-6,170	-13,060	-18,063	-20,831	-21,751	-12,624	-9,225	-7,481	-6,171	-5,821	-6,122	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
- stock right
-	-	-	-	-	-	-	-	-	-	223	651	589	1,331	660	254	328	-413	34	12	0	0	0	-	-	-	-	-	-	-	-
- warrant liability
-	-	-	-	-	-	-	-	-	-	40	249	330	998	1,253	1,993	1,971	1,303	951	3	0	0	0	-	-	-	-	-	-	-	-
Noncash charge for change in warrant terms
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Issuance of common stock and warrants for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Noncash charge for common stock anti-dilution issuance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Noncash charge for accretion of debt discount
-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncash charge for note conversion to common stock
-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of patents
-	-	-	-	-	-	-	-	-	-	0	149	149	149	149	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Noncash capital contribution
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Noncash conversion of accrued expenses into equity
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Noncash income related to change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	371	0	0	0
Stock-based compensation
12,673	11,336	12,393	12,131	15,293	13,370	9,687	6,993	825	101	18	26	77	72	141	156	-301	190	365	480	1,438	1,209	1,311	1,297	908	841	695	724	0	0	0
Depreciation
73	87	163	220	228	216	136	72	54	39	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of operating lease right-of-use asset
460	472	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	40	44	47	57	72	93	118	138	149	177	249	296	335	349	330	316	304	293	0	0	0
Impairment of goodwill
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	249	249	249	64	0	0	0
Write-off of intangibles
-	-	-	-	-	-	-	-	-	-	1,000	2,600	3,300	1,500	3,300	1,700	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Tax
-	-	-	-	-	-	-	-	-	-	-400	-1,040	-1,320	-1,720	-1,320	-680	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Write-off of intangibles
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Write-off of prepaid research supplies
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	669	669	669	669	0	0	0	0	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	-	6	22	38	54	64	62	60	-9	-70	-85	0	0	0	-	-	-	-	-	-	-	-
Amortization of debt discount
596	535	0	0	0	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Amortization of premiums and discounts on investments
298	301	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued interest on convertible loan
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Amortization of deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Loss on settlement of warrant liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,724	0	0	0
Loss on extinguishment of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Prepaid expenses and other current assets
307	-83	829	638	1,173	1,080	563	95	25	-709	-909	-822	-671	-270	-210	-223	-50	215	93	-48	-464	-775	-753	-868	-512	192	106	370	0	0	0
Security deposit
-	-	-	-	-	-	-	-	-	-	-45	-40	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Other Asset
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-851	1,124	338	378	70	-780	504	1,167	882	-583	-1,215	-1,078	-684	130	-29	-141	-595	-1,241	-438	-669	-82	418	-799	-145	-362	-608	71	42	0	0	0
Accrued expenses
-1,029	-1,300	1,413	3,353	1,056	3,999	2,265	861	2,451	929	356	446	60	-180	-82	-155	-548	-638	-665	-507	-126	241	431	305	406	159	122	112	0	0	0
Operating lease liabilities
-460	-472	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-42,127	-39,391	-39,194	-35,971	-34,858	-31,367	-31,764	-24,241	-18,901	-15,935	-7,051	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-3,936	-3,902	0	0	0
Cash flows from investing activities:
Purchases of marketable securities
-	67,214	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from maturities of marketable securities
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment in restricted bank deposit
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-75	-112	-150	37	75	0	0	0	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,676	-5,382	-5,992	-6,537	-7,344	0	0	0	-	-	-	-	-	-	-	-
Proceeds from sale of patents
-	-	-	-	-	-	-	-	-	-	0	50	50	50	50	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Capitalized patent costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	136	814	791	742	624	543	528	524	527	0	0	0
Purchase of property and equipment
-	40	142	150	194	235	215	242	220	237	0	0	0	-	-	-	-	-	-	122	120	114	77	3	0	0	0	1	0	0	0
Cash received (paid) for long-term deposits
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	457	271	75	-259	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by (used in) investing activities
-8,793	-33,524	-42,782	-27,081	-9,202	-317	-156	-119	-75	-114	-46	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-524	-529	0	0	0
Cash flows from financing activities:
Proceeds from debt financing obligation
-	15,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of debt issuance costs
-	276	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of term loan principal
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercises of stock options
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of common stock under at-the-market sales agreement
-	-	-	-	0	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment for settlement of taxes upon vesting of restricted stock units
390	1,378	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from grant
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Repayment of line of credit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12	0	0	0
Proceeds from issuance of preferred stock and warrants, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Redemption of convertible notes and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Proceeds from convertible loan and related financial derivative into Series C preferred stock
-	-	-	-	-	-	-	-	-	2,500	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from advances from collaboration partners
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock and warrants, net and exercise of warrants and options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,152	5,979	5,979	5,979	4,827	75	4,052	10,917	10,917	11,944	10,815	3,950	4,044	0	0	0
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,152	5,979	5,979	5,979	4,827	0	0	0	-	-	-	-	-	-	-	-
Net cash (used in) provided by financing activities
32,217	46,800	0	0	0	-	-	-	-	37,950	18,669	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	3,938	4,032	0	0	0
Effect of exchange rate on cash
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase (decrease) in cash, cash equivalents and restricted cash
-18,703	-26,115	-33,187	-14,141	26,229	24,500	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reconciliation of cash, cash equivalents and restricted cash to condensed consolidated balance sheets:
Decrease in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	670	-777	-1,743	-2,217	-3,067	-2,523	1,055	259	-482	-2,776	-5,728	-4,014	3,047	4,509	4,616	5,481	-522	-399	0	0	0
Dividends accrued on preferred stock
-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	0	0	4	-	4	14	20	14	0	0	0	-	-	0	0
Deemed dividend - preferred stock
-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of cash flow activities:
Cash paid for interest
1,165	986	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of non-cash financing activities:
Non-cash acquisition of treasury stock
-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value of warrants issued in connection with long-term debt
-	421	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion of convertible loan into Series C preferred stock
-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion of preferred stock into common stock
-	-	-	-	-	-	-	-	-	-	61	17	5	1	0	6	7	7	7	0	0	0	-72	0	0	0	0	-	-	0	0
Allocation of equity proceeds to warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	559	2,301	2,301	2,301	1,742	0	0	0	-	-	-	-	-	-	-	-
Allocation of equity proceeds to stock rights
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	142	917	917	917	775	0	0	0	-	-	-	-	-	-	-	-
Allocation of preferred stock proceeds to beneficial conversion feature
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	135	926	926	926	790	0	0	0	-	-	-	-	-	-	-	-
Warrants issued for financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Issuance expenses of Series C Preferred Shares
-	-	-	-	-	-	-	-	-	-	10	0	0	0	0	-	-	-	-	-	-	-	-	118	0	0	0	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	2	21	54	85	117	117	119	122	0	0	0